Prevention of liver cancer and care of people living with Chronic Hepatitis B. Presenters Dr. Nicole Allard and Vanessa Towell.
|
|
- Catherine Stafford
- 5 years ago
- Views:
Transcription
1 Prevention of liver cancer and care of people living with Chronic Hepatitis B. Presenters Dr. Nicole Allard and Vanessa Towell.
2
3 Pre and post test questionnaire
4 1. In Australia the main burden of Chronic hepatitis B is in people born in Asia True False
5 2. Aboriginal people are one of the priority communities affected by CHB True False
6 3. Hepatitis B causes liver cancer True False
7 4. The majority of people living with CHB do not need ongoing management True False
8 5. The presence of HBsAg in a 40 year old born in China needs a further test at 6 month to confirm CHB infection True False
9 6. CHB patients born in Africa with chronic hepatitis B should be screened for liver cancer from the age of 20. True False
10 7. There is treatment available for chronic hepatitis B True False
11 8. Treatment reduces liver scarring but not risk of cancer True False
12 9. Pregnant women and their children are normal managed and followed up by specialist services True False
13 10. Cancer screening is aimed to detect cancers early rather than prevent cancer True False
14 Declaration Nicole Allard Has received no pharmaceutical company support or sponsorship Advisory COC for ASHM Vanessa Towell Has received no pharmaceutical company support or sponsorship
15 Acknowledgement Slides: presentation adapted from relevant section of Advanced Management of Hepatitis B course for general practitioners developed by ASHM and also includes material from VIDRL presentations and ML mapping project.
16 Objectives include to understand Epidemiology Natural History Who and how to test Role of primary care in care and cancer screening How to develop a GPMP for CHB
17 Global epidemiology Major health issue worldwide ~ 350 million with CHB, 500, ,000 deaths annually most infected perinatally Estimated to be the 10 th leading cause of death worldwide 2 nd most important human carcinogen, after tobacco HCC 5th most common cause of cancer, 3 rd most common cause of cancer related mortality China deaths over 300,000 per year 80% CHB WHO fact sheet, Chen 2011
18 Source: et/index.htm
19 Lavanchy 2004
20 Epidemiology in Australia Most reliable Australian estimate: 218,000 people with chronic hepatitis B, over 2 million ever infected J MacLachlan, ANZJPH 2013
21 Mortality Chronic hepatitis B: 15-25% will die from the complications of cirrhosis or from hepatocellular carcinoma (HCC) without appropriate treatment and care Ref: Fattovich J Hepatol 2008
22 Liver cancer and ATSI Indigenous Australians are 3 times as likely to develop, and 3.3 times as likely to die from liver cancer and had a lower chance of surviving another 1 year (21% compared with 33%). ( Australian Institute of Health and Welfare report 2013) higher prevalence of hepatitis B infection 3.7% in this population group is a contributing factor.
23 HBV vaccination in Australia Vaccine available since 1984 Aboriginal and Torres Strait Islander people in NT since 1990 Adolescent catch up program 1998 Universal infant vaccination 2000.so why is it an ongoing issue? National Immunisation Handbook 2013
24 Australian permanent migration data High >8% Intermediate 2 8% Low <2% 0 Source: Dept of immigration permanent migration data
25 Chronic Hepatitis B in Australia 218,000 living with CHB 112,000 diagnosed 25,000 in care J MacLachlan ANZJPH 2013, NNDSS, Medicare data
26 Viral Load and Incidence of Cirrhosis Cumulative incidence of liver cirrhosis (% subjects) Baseline HBV DNA level, copies/ml 10 6 (n=602) 10 5 <10 6 (n=333) 10 4 <10 5 (n=628) 300 <10 4 (n=1,150) <300 (n=869) Log rank test of trend p< Year of follow up Cumulative Incidence of Liver Cirrhosis All Subjects (n=3,582) 36.2% 23.5% 9.8% 5.9% 4.5% Iloeje UH, et al. Gastroenterology. 2006;130;
27 Viral Load and Incidence of HCC Cumulative incidence of HCC (%) Cumulative Incidence of HCC: All Subjects (n=3,653) Baseline HBV DNA Level, copies/ml < < <10 4 < Year of follow up 14.89% 12.17% 3.57% 1.37% 1.30% Chen CJ, et al. JAMA. 2006;295:65 73.
28 Cancer in New South Wales Incidence and Mortality Report 2008
29 J MacLachlan VIDRL 2012
30 Micro epidemiology Consider your own practice and interests Individual practices may not reflect population in LGA Special interests refugee health, HIV medicine, drug and alcohol, student health
31 Task 1 My patients Newly arrived refugees Pakistan, Burma, Afghani, Iran CHB 56% Sudanese, 4% Vietnamese JOSLIN CLINIC Community health Low SES Women s health Mental health Refugees, BVE, Iran, Burma Sudanese from mid 2000 IDU Old Foostcray (union) Shared care MARIBYRNONG Inner western Melb. 50% born overseas 58% Aust. born have both Parents born overseas Low SES and gentrification 44% 2 languages at home Vietnamese 10% Chinese 3% Indian4%
32 Testing
33 Who to test People born in Asia, Africa, Middle East, Pacific Islands, Eastern & Southern Europe Sexual and household contacts and family members of people with hepatitis B Aboriginal and Torres Strait Islanders Pregnant women Men who have sex with men, people who inject drugs, Sex workers, haemodialysis patients, people with another STI, hepatitis C or HIV infection, everyone prior to receiving cytotoxics or immunosuppressive therapy, people with elevated ALT/AST of unknown aetiology ASHM testing portal
34 What tests should we order? If chronic infection HBsAg anti-hbc (= HBcAb) anti-hbs (= HBsAb) DON T order HEPATITIS B SEROLOGY In suspected acute infection IgM anti- HBc
35 Interpretation of HBV serology HBsAg anti HBc anti HBs negative negative negative susceptible HBsAg anti HBc anti HBs negative positive positive resolved HBV infection HBsAg anti HBc anti HBs negative negative positive vaccinated HBsAg anti HBc IgM anti HBc * anti HBs positive positive positive negative (high titre)* acute HBV infection HBsAg anti HBc IgM anti HBc anti HBs positive positive negative negative chronic HBV infection HBsAg anti HBc anti HBs negative positive negative various possibilities Mast 2006
36 A brief note on isolated core anti-hbc Most common associated with low titre anti-hbs <10 IU/ML and person is naturally immune HBV DNA not on Medicare for testing in this setting Occasionally represent occult infection May be a false positive anti-hbc + May be recovering from acute HBV infection Important in HIV, HCV, liver disease person about to undergo chemotherapy
37 Conveying positive results Use an interpreter where appropriate (check translation of virus ) providing information about the legal considerations around disclosure of hepatitis B status and the provision of information about (and referral to) available to support services Deliver information in more than one form (resources HepB help, ASHM, Cancer council, hepatitis organisations) Arrange for follow up appointment to answer questions and to review further testing ASHM website for hbv testing/ conveying hepatitis b test results
38 Disclosure Sexual partners Workplace Family and extended family Patient living with CHB Childcare centre or school Friends & Community Sporting club
39 Negative results If negative and not immune offer vaccination Vaccination recommended for: Household or household like contacts, sexual contacts, men who have sex with men, migrants from endemic countries, ATSI, haemodialysis patients and patient where haemodyalysis is anticipated, transplant recipients, HIV positive adults and other immunocompromised adults, people with liver disease or hepatitis C, person with developmental disabilities attending residential or non residential facilities, People who inject drugs, sex industry workers and other persons at occupational risk, travelers to endemic areas. BUT NOT ALWAYS FREE (check in your state) Ref: The Australian Immunisation handbook 10 th edition 2013
40 Task 2 HBsAg Anti HBc Anti HBs Person immune from exposure to the virus as a child in China Health care worker successfully immunised last year Person living with CHB
41 Task 2 HBsAg Anti HBc Anti HBs Person immune from exposure to the virus as a child in China + + Health care worker successfully immunised last year Person living with CHB + + +
42 Natural history, monitoring and cancer screening
43 ASHM resource
44 Initial Assessment of patients with CHB 1. History, Family History esp. history of liver cancer and physical examination 2. Viral markers hepatitis B surface antigen (HBsAg) hepatitis B e-antigen (HBeAg); anti-hbe serum hepatitis B virus (HBV) DNA testing for anti-hav, anti-hcv, anti-hdv and anti-hiv 3. Markers of liver disease liver enzymes ALT and AST markers of liver function Serum bilirubin, albumin, INR, AFP, FBC (platelets) Imaging (usually ultrasound) 4. Evaluation for co-morbidities Alcohol, drug abuse, diabetes
45 ALT VALUES and significance Laboratories will vary in reporting of abnormal range >50 FOR women ALT > 20 FOR men ALT > 30 On diagnosis order more than once before deciding on phase e.g. 2-3 times over 3 month period
46 FibroScan Available in most large hepatitis clinics portable units Procedure well validated and reproducible Takes approximately 5 minutes Can be easily repeated on serial basis Can accurately determine if someone has minimal fibrosis or severe fibrosis/cirrhosis ASHM 2012
47 Cancer screening Cancer screening is part of routine monitoring for specific groups African men and women from >20 Asian men for the age of >40 Asian women from the age of >50 Aboriginal and Torres Strait Islander people >50* Patients with cirrhosis Patients with a family history of HCC Ref:
48 Cancer screening participation in established supported programs Cervical cancer 57% Breast 56% Bowel 38% Participation affected by remoteness, SES, CALD& ATSI AIHW 2013, Breast Screen
49 Cancer screening Ultrasound and AFP 6 monthly A new lesion need further assessment with quadruple phase CT and specialist review US report can vary in quality EARLY DETECTION NOT PREVENTION
50 Cancer screening Diagnoses smaller cancers better characteristics less vascular invasion Increases median survival 977 vs 253 days Higher proportion can be treated with curative intent (68% vs 30%) Wong et al. Internal Med Journal 2012
51 Anti viral treatment
52 Progression to Chronic HBV Infection Acute (6 months) HBeAg Chronic (Years) anti HBe HBsAg Titre Total anti HBc IgM anti HBc Years Weeks after exposure
53 HBeAg Positive High HBV DNA Elevated ALT Abnormal Liver Biopsy HBeAg Negative High HBV DNA Elevated ALT Abnormal Liver Biopsy
54 Anti Viral treatment Treatment can reverse fibrosis in the liver and prevent further damage Reduces the risk of cancer up to 75% over 5 years Reduces infectivity and mother to child transmission Reduces mortality May result in HBeAg seroconversion or rarely HBsAg Is cost effective as HCC prevention Papatheodoridis 2010, Kim 2012, Kumada 2012, Hosaka 2013, Robotin 2009
55 Treatment Treatment-Naïve patients PegIFN alfa 2a consider Phase 2 HBeAg Entecavir (well tolerated, low resistance at 5 years) Tenofovir (women of childbearing age, HIV co infection, renal function testing, low/no resistance at 5 years) Lamivudine-Resistant patients Tenofovir ± Lamivudine
56 Definitions of Response in CHB Suppression of HBV DNA and normalisation of ALT Achievable and Effective Endpoint HBeAg loss HBeAg seroconversion HBsAg loss HBsAg seroconversion Major trial endpoint Optimal endpoint
57 All patients All patients need yearly viral load and liver function tests done 6 monthly Should be assessed for cirrhosis using FibroScan specialist referral There is no such thing as a HEALTHY CARRIER
58 Pregnancy High viral load > 10,000,000 IU/ml is associated with increased risk of transmission to newborn Pregnancy is a relatively immune tolerant state All women need HBV DNA during pregnancy and referral for assessment This is not always done by specialist services Glies 2013, Gurguis
59 .so how well are we doing that? 2 Sydney Hospitals 14,857 Births 295 CHB antenatal patients 98% born overseas 3 Victorian hospitals 46,855 Births 398 CHB antenatal patients 87% born overseas HBeAg 65% DNA 3.5% Specialist care 7% HBeAg 33% DNA 20% Specialist care 18% Ref: Guirgis, M JGHF 2009 and Giles et al ANZJOG 2013
60 213 HBsAg +ve mother followed, 138 infants tested 4 positive All babies received HBIG and birth dose HBV <12 hours Transmission related to viral load Birth dose is as/more important than HBIG Specialist care Lamivudine or Tenofovir until 3 months post partum Wiseman et al MJA 2009
61 Co infection HDV/HIV/HCV or combination Outcomes worse liver disease, HCC and mortality Specialist management as co infection complicates treatment choice
62 Steps for management 1. work out phase of disease 2. arrange appropriate referral or monitoring 3. cancer (HCC) screening if required 4. HAV vaccination (if not immune)
63 Steps for management in GP (2) 5. Lifestyle advice 6. Information about how you can and can not transmit HBV 7. contact tracing and vaccination of contacts and advise testing of the wider family
64 Case study 50 year old Somali man CHB 2003 previously yearly bloods anti- HBe, viral load 1560 IU/ml, ALT 19 BMI 35 Yearly viral load 24,000 ALT 30 Ultrasound new lesion?haemangioma 9mm x 10mm
65 Case study Mr. BK 30 year old born Afghanistan, Entecavir in Pakistan for one year arrived 2012 screened in detention centre VL 560 IU/ml, HBeAg ve, HBeAB +ve, ALT 20, BMI 24, alcohol intake rarely, Platelets 121, Bilirubin 35
66 Case study A. Mr. N 50 year man B. Mr. K 45 year old C. Mr. N 42 year old HBsAg anti HBc anti HBs + < D. Mr. T 22 year old >100
67 Challenges Priority populations are often disadvantaged in terms of access to services Health literacy Stigma and discrimination CALD and ATSI Lower participation rates in cancer screening programs that are supported breast, cervical and bowel
68 Challenges Poor care during pregnancy DNA not performed, timely? birth dose <24 hours Low Rates of follow up of infants born to CHB+ mothers and their families Loss to follow up as child transitions to adult services Contact tracing not done Ref: Giles 2013, Jimenez 2013, Joslin Clinic IHBS, Williams 2011
69 Challenges Improving screening in affected communities Increasing numbers on treatment to prevent mortality and morbidity 3-5% Adherence to long term anti viral medication Monitoring over many years (OPD 30% FTA, Joslin 15%) VIDRL, NDDSS, WRHC, Western Hospital
70 Task 3: Develop a GPMP Mrs A 34 year old Sudanese woman 3 children 10, 4, 2 years CHB dx: on screening 2004 briefly in specialist care at WH after 3 rd pregnancy, BMI 30 no alcohol no family history cancer 6 monthly tests US normal, AFP 20, AST 50, viral load 20,000,000 HBeAg negative
71 Develop a GPMP KD 17 year old Tibetan high school student dx 2011 at screening in paediatric care, father died 40 years Ca on arrival in Australia abdominal cancer, HBeAg positive, viral load 170,000 ALT 18, BMI 21
72 ASHM 2012
73 GPs and prescribing Pilot in NSW with GP prescribing Recognised as part of First National Hepatitis B Strategy general-schedule.pdf Page 537 A general practitioner or non-specialist hospital doctor may only prescribe Highly Specialised Drugs to provide maintenance therapy under the guidance of the treating specialist Prescriptions for Highly Specialised Drugs can be dispensed by an approved private hospital s dispensary or by a community pharmacy
74 Interested in more? ASHM run courses introductory and advanced management Online learning module through GP Learning
75 References and resources The Australian Immunisation handbook 10 th edition 2013 ASHM: National testing policy ASHM 2008 B positive: All you need to know about hepatitis B a guide for primary providers (currently under review) 20positive/b_positive-all_you_wanted_to_know.pdf ASHM Decision making in hepatitis B 20sheets/hbv/decision_making_hbv.pdf Antenatal guidelines (NSW focus)
76 Information and patient resources: Hepatitis Asutralia HepB Help Cancer Council Help Line The Australian Injecting and Illicit Drug Users League (AIVL) Telephone: The Multicultural Health and Support Service
77 Thank you To VIDRL epidemiology unit, Dr B Cowie and J Maclachlan, ASHM, WRHC, Dr Karen Linton Dr Tom Schulz, Integrated Hepatitis B service from RMH Tracey Cabrie and Jacqui Richmond This work supported by APA scholarship
Management of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More information9/26/2014. Epidemiology of chronic hepatitis B in key priority populations. Declaration of Interest. Advisory. Prevalence - similarities
Epidemiology of chronic hepatitis B in key priority populations Declaration of Interest I receive no funding of any kind from any pharmaceutical company Benjamin Cowie WHO Regional Reference Laboratory
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationHepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia
Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia Tilman Ruff Nossal Institute for Global Health, University of Melbourne Consultant: Australian
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationX-Plain Hepatitis B Reference Summary
X-Plain Hepatitis B Reference Summary Introduction Hepatitis B is the most common serious liver infection. It is caused by the hepatitis B virus that attacks the liver. The virus is transmitted through
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHow does HBV affect the liver?
Hepatitis B Why is the liver important? Your liver is a vital organ that performs many essential functions. It s the largest solid organ in the body and is located under your rib cage on the upper right
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationkeyword: hepatitis Hepatitis
www.bpac.org.nz keyword: hepatitis Hepatitis Key reviewers: Dr Susan Taylor, Microbiologist, Diagnostic Medlab, Auckland Dr Tim Blackmore, Infectious Diseases Physician and Microbiologist, Wellington Hospital,
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationManagement of Patients with Chronic Hepatitis B: The Alaska Experience
Management of Patients with Chronic Hepatitis B: The Alaska Experience Brian J McMahon, MACP, FAASLD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Disclosures I have no conflicts
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationNHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme
NHS public health functions agreement 2017-18 Service specification No.1 Neonatal hepatitis B immunisation programme NHS public health functions agreement 2017-18 Service specification No.1Neonatal hepatitis
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationTreatment for Hepatitis B
Introduction This Fact Sheet is for people with chronic hepatitis B (CHB) who need treatment. Chronic hepatitis B is diagnosed by a positive hepatitis B surface antigen (HBsAg) which has been present for
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationHepatitis B at a Glance
Return completed form, preferably within 30 days of U.S. date of arrival, to address on reverse side of this form. Review overseas medical exam if available and document immunization dates. Indicate if
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives
On the Liver Disease Front Lines: Hepatitis A, B and C Prevention and Treatment Kurt Cook, MD, MSc ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationManagement of Hepatitis B
Management of Hepatitis B Background HBV is contracted either sexually or by blood to blood transmission. The combined prevalence of HBV and HCV is just over 2% in the UK. More than 95% of immune competent
More information>Hepatitis NSW will continue to
Continued Equal Treatment Access to hepatitis C medicines KURT SAYS Everyone with viral hepatitis deserves equal access to treatment. Thankfully Australians can access hepatitis C treatment before they
More informationObjectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018
10/15/2018 Objectives Hepatitis C Screening, Treatment and the Family Physician Wayne Ghesquiere MD FRCPC Infectious Diseases & Internal Medicine Division of Infectious Diseases Victoria, BC At the end
More informationAbnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital
Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital www.migrationobservatory.ox.ac.uk Migrants in London Migrants in London Migrants in London Common liver
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationDEPARTMENT OF GENITO-URINARY MEDICINE HEPATITIS B
DEPARTMENT OF GENITO-URINARY MEDICINE MAIN TRANSMISSION ROUTES HEPATITIS B Sexual transmission Occurs in unvaccinated/non immune men who have sex with men and correlates with multiple partners, unprotected
More informationAn Introduction to HIV Shared Care for GPs
An Introduction to HIV Shared Care for GPs Managing HIV as a chronic condition With effective antiretroviral therapy (ART), HIV infection is now considered a chronic condition and people living with HIV
More informationHepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. Vana Papaevangelou (Greece) National and Kapodistrian University of Athens Chang SemFNM
More informationChronic Hepatitis B. What every GP should know. Prof Ed Gane NZ Liver Unit
Chronic Hepatitis B What every GP should know Prof Ed Gane Z Liver Unit Case 1 55 Yr old Tonga male»well but dad died of liver cancer»lfts: ALT 85, GGT 60; ALP 75; bilirubin 12 What next? Case 1 55 Yr
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationThe challenge of liver cancer surveillance in general practice: Do recall and reminder systems hold the answer?
RESEARCH The challenge of liver cancer surveillance in general practice: Do recall and reminder systems hold the answer? Nicole Allard, Tracey Cabrie, Emily Wheeler, Jacqui Richmond, Jennifer MacLachlan,
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.1 Neonatal hepatitis B immunisation programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More informationThe facts you need to know
Hepatitis B The facts you need to know Patient information booklet Know it. Test it. Treat it. Table of contents About this booklet 3 What is hepatitis? 3 What is chronic hepatitis B? 3 Can someone be
More informationPERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases
PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases Viruses in July (ViJ), 2004 Overview Epidemiology Perinatal transmission
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationHepatitis B in Queensland: A situation analysis, May 2011
Hepatitis B in Queensland: A situation analysis May 2011 1 Hepatitis B in Queensland: A situation analysis, May 2011 This paper provides a summary of key findings from the work undertaken to date by the
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationHepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationArm yourself against Hep B! Vaccinate
Arm yourself against Hep B! Vaccinate Arm yourself against Hep B! Vaccinate Written by Injecting Drug Users for Injecting Drug Users Why it s important for injecting drug users to know about and understand
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationMaitines septiembre de 2011 Francisco Jorquera Plaza
Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas
More informationGlobal reporting system for hepatitis (GRSH) project description
Global reporting system for hepatitis (GRSH) project description Contents 1. Background... 2 2. Target audience for this document... 2 3. Data to be reported through the Global Reporting System for Hepatitis...
More informationChronic hepatitis B. A clinical audit of GP management. Hepatitis B virus (HBV) infection represents a growing health burden
professional Anouk Dev James Ngoc Huong Nguyen Lili Munafo Eve Hardie Linda Iacono Chronic hepatitis B A clinical audit of GP management Background Hepatitis B virus (HBV) infection represents a growing
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Volume 12, Issue 4 December, 2013 Overview Prevention of Perinatal Hepatitis B Transmission Perinatal transmission of hepatitis B virus (HBV) is preventable through universal
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationHepatitis B vaccination worldwide: Lessons learnt and the way forward
Hepatitis B vaccination worldwide: Lessons learnt and the way forward VHPB Russia meeting Oct 2018 Pierre Van Damme MD, PhD History Hepatitis B vaccines have been available since early 1980 s First recommended
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationEpidemiology of hepatitis B and D in Greece
Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationHepatitis B Vaccination and Prevention. Angela M. Jo, MD, MSHS
Hepatitis B Vaccination and Prevention Angela M. Jo, MD, MSHS What is Hepatitis B? A virus that lives in blood and other bodily fluids An infectious disease that causes liver disease and cancer 100 x more
More informationCarrier state and chronic infection state. At-risk populations
John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology and Nutrition Carrier state and chronic infection state -
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationAPPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College
APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for
More information